■Abstract #19LBA

切除不能進行・再発大腸癌患者に対する1st-line治療としてのmFOLFOX6 + Sorafenib療法の有用性を検討したプラセボ対照二重盲検無作為化比較第IIb相試験：RESPECT試験

A Phase 2b, Double-Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared With Placebo (PBO) When Administered in Combination With Chemotherapy (Modified FOLFOX6) for First-line Treatment (tx) of Patients (Pts) With Metastatic Colorectal Cancer (mCRC). The RESPECT Trial.

Josep Tabernero, et al.

■Abstract #6005/6099

化学療法不応の切除不能進行・再発大腸癌患者に対するTAS-102 + BSC療法の多施設共同無作為化二重盲検比較第II相試験：主要結果と効果予測バイオマーカー (TK1およびTP発現) に関する報告

Abstract #6005

A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC)

Yasutoshi Kuboki, et al.

Abstract #6099

The Value of Thymidine Kinase 1 (TK1) and Thymidine Phosphorylase (TP) Expression as Predictive Factors With the Treatment Efficacy of TAS-102, a Novel Antitumor Agent, in Patients (pts) With Metastatic Colorectal Cancer (mCRC)

Yoshito Komatsu, et al.

■Abstract #6007/6097

既治療の切除不能進行・再発大腸癌患者に対するIrinotecanとPanitumumabまたはCiclosporinの併用療法：PICCOLO試験の結果報告

Abstract #6007

遺伝子変異によるCPT-11療法 vs. CPT-11 + Panitumumab療法の有効性の検討

Panitumumab in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer - Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification

Matthew T. Seymour, et al.

Abstract #6097

CPT-11療法 vs. 低用量CPT-11 + Ciclosporin療法の検討

Ciclosporin in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer - Results of PICCOLO, a Large Randomised Trial with Prospective Molecular Stratification

Gary W. Middleton, et al.

■Abstract #6LBA

切除不能進行・再発大腸癌既治療例に対するFOLFIRI + Aflibercept療法の検討：プラセボ対照無作為化比較第III相VELOUR試験の結果から

Results From VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC)

Josep Tabernero, et al.

■Abstract #33LBA/6014

切除不能進行・再発大腸癌に対する抗EGFR抗体薬の効果予測因子としてのKRAS codon 12,13変異

Abstract #33LBA

切除不能進行・再発大腸癌における予後ならびにPanitumumabの効果予測因子としてのKRAS codon 12および13変異の評価

Evaluation of Individual Codon 12 and 13 Mutant (MT) KRAS Alleles as Prognostic and Predictive Biomarkers of Response to Panitumumab (pmab) in Patients with Metastatic Colorectal Cancer (mCRC)

Marc Peeters, et al.

Abstract #6014

KRAS 遺伝子p.G13D変異を有する切除不能進行・再発大腸癌は日本人患者においてprogression-free survivalを延長する可能性がある

Cetuximab Treatment for Metastatic Colorectal Cancer With KRAS p.G13D Mutation May Improve Progression-free Survival in Japanese Patients

Masahiko Osako, et al.

■Abstract #6005/6099

化学療法不応の切除不能進行・再発大腸癌患者に対するTAS-102 + BSC療法の多施設共同無作為化二重盲検比較第II相試験：主要結果と効果予測バイオマーカー (TK1およびTP発現) に関する報告

Abstract #6005

A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC)

Yasutoshi Kuboki, et al.

Abstract #6099

The Value of Thymidine Kinase 1 (TK1) and Thymidine Phosphorylase (TP) Expression as Predictive Factors With the Treatment Efficacy of TAS-102, a Novel Antitumor Agent, in Patients (pts) With Metastatic Colorectal Cancer (mCRC)

Yoshito Komatsu, et al.

■Abstract #6007/6097

既治療の切除不能進行・再発大腸癌患者に対するIrinotecanとPanitumumabまたはCiclosporinの併用療法：PICCOLO試験の結果報告

Abstract #6007

遺伝子変異によるCPT-11療法 vs. CPT-11 + Panitumumab療法の有効性の検討

Panitumumab in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer - Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification

Matthew T. Seymour, et al.

Abstract #6097

CPT-11療法 vs. 低用量CPT-11 + Ciclosporin療法の検討

Ciclosporin in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer - Results of PICCOLO, a Large Randomised Trial with Prospective Molecular Stratification

Gary W. Middleton, et al.

■Abstract #6009/6040

大腸癌肝転移に対するConversion therapy

Abstract #6009

大腸癌肝転移症例におけるFOLFOX、FOLFIRIにCetuximabを併用した術前補助化学療法のPFSとOSへの影響―CELIM試験の結果から

Progression Free and Overall Survival After Neoadjuvant Treatment of Colorectal Liver Metastases With Cetuximab Plus FOLFOX or FOLFIRI - Results of the CELIM Study

Gunnar Folprecht, et al.

Abstract #6040

大腸癌肝限局転移症例における外科的切除および化学療法の影響

Liver Only Metastatic Disease in Patients With Metastatic Colorectal Cancer (mCRC), Impact of Surgery and Chemotherapy

Sarwan Bishnoi, et al.

■Abstract #6013/6150

BBP (Bevacizumab beyond progression) をめぐる検討: ARIES観察研究の時間依存性解析と米国の実臨床データの解析から

Abstract #6013

切除不能進行・再発大腸癌におけるPD後のBevacizumab累積投与量は生存延長と相関する: ARIES観察研究の時間依存性解析

Cumulative Exposure to Bevacizumab (BV) After Progression Correlates With Increased Survival in Patients (pts) With Metastatic Colorectal Cancer (mCRC): a Time-dependent Analysis of the ARIES Observational Cohort Study

Axel Grothey, et al.

Abstract #6150

BBPを施行された切除不能進行・再発大腸癌患者の臨床転帰

Survival Outcomes With Use of Bevacizumab Beyond Progression (BBP) in Metastatic Colorectal Cancer (mCRC) Patients (Pts)

Thomas Cartwright, et al.

■Abstract #6132

Oxaliplatin ± Bevacizumab治療歴を有するKRAS 遺伝子野生型の切除不能進行・再発大腸癌患者に対するPanitumumab + FOLFIRI療法とFOLFIRI療法の有効性の比較: 20050181試験の結果から

Efficacy of Panitumumab Plus FOLFIRI Versus FOLFIRI Alone in Patients With Wild-Type (WT) KRAS Metastatic Colorectal Cancer (mCRC) Treated With Prior Oxaliplatin or Bevacizumab Regimens: Results From 20050181

Timothy Price, et al.

■Abstract #6144

KRAS 野生型切除不能進行・再発大腸癌に対するPanitumumab + Irinotecan 併用療法を検討した第II相試験: GERCOR試験

Phase II Study of Panitumumab With Irinotecan for Patients With KRAS Wild-type Metastatic Colorectal Cancer (mCRC) Refractory to Standard Chemotherapy - A GERCOR Study

Thierry André, et al.

■Abstract #803

転移を有する膵癌患者に対するGemcitabine + Erlotinib±Bevacizumab療法を検討した無作為化比較第III相試験 (AVITA試験): 血液生化学的バイオマーカーの解析

Analysis of Blood Plasma Factors in the Phase III AVITA Randomise, Placebo-controlled Study of Gemcitabine + Erlotinib with or without Bevacizumab in Patients with Metastatic Pancreatic Cancer.

Eric Van Cutsem, et al.

■Abstract #6504

切除不能局所進行または転移を有する胃・胃食道接合部腺癌患者に対する1st-line治療としてのEpirubicin + Cisplatin + Capecitabine (ECX) + Rilotumumab併用療法の有効性および安全性の検討

Safety and Efficacy of Epirubicin, Cisplatin, and Capecitabine (ECX) Plus Rilotumumab (R) as First-line Treatment for Unresectable Locally Advanced (LA) or Metastatic (M) Gastric or Esophagogastric Junction (EGJ) Adenocarcinoma

Timothy Iveson, et al.

■Abstract #6505

漿膜浸潤を伴う進行胃癌に対する術後補助化学療法としてのCisplatin腹腔内投与 + 早期Mitomycin-C + 長期Doxifluridine + Cisplatin療法 (iceMFP) vs. Mitomycin-C +短期Doxifluridine療法 (Mf) + 無作為化比較第III相試験: AMC 0101試験の最新報告

Update of AMC 0101 Study: a Randomized Phase III Trial of Intraperitoneal Cisplatin and Early Mitomycin-C Plus Long-term Doxifluridine Plus Cisplatin (iceMFP) Versus Mitomycin-C Plus Short-Term Doxifluridine (Mf) as Postoperative Adjuvant Chemotherapy for Grossly Serosa-positive Advanced Gastric Cancer (NCT00296322)

Min-Hee Ryu, et al.

■Abstract #14LBA

切除不能進行・再発大腸癌患者に対する1st-line治療としてのmFOLFOX6 + BIBF 1120療法 vs. mFOLFOX6 + Bevacizumab療法のオープンラベル無作為化比較第I / II相試験

A Phase I/II, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer

Eric Van Cutsem, et al.